What the applicant submits

Route 92 Medical, Inc. appears in FDA 510(k) data at 155 Bovet Rd., Suite 100, San Mateo, CA 94402, a filing address rather than a confirmed headquarters. The two records in this sample are K260220, "Route 92 Medical Full Length 046 Access System," received January 26, 2026 and decided September 16, 2026, and K263266, "Route 92 Medical Full Length 046 Reperfusion System and Aspiration Tubing Set," received September 18, 2026 and decided October 16, 2026. Both carry decision code SESE, described as Substantially Equivalent, under regulation number 870.1250, device class 2, with a Cardiovascular advisory committee and Neurology review panel [1][2][3].

Documented products and technologies

The two filings sit under different product codes: QJP for the Access System, classified as "Catheter, Percutaneous, Neurovasculature," and NRY for the Reperfusion System and Aspiration Tubing Set, classified as "Catheter, Thrombus Retriever" [1][2]. K260220 was a Traditional clearance; K263266 was a Special clearance, and the FDA page for K263266 lists no third-party review and no authorized predetermined change control plan [2][3]. The K260220 clearance letter is linked for readers to check its complete scope [4].

A separate 2025 decision letter for K243601 covers the "Route 92 Medical HiPoint Reperfusion System and Aspiration Tubing Set," naming an aspiration catheter, delivery catheter and Base Camp Sheath, used with an aspiration tubing set and a compatible vacuum pump [8]. The company website describes FreeClimb catheter systems and the HiPoint Reperfusion System, with the latter marked as an investigational device limited by federal law to investigational use [6]. Those are manufacturer statements, distinct from FDA clearance scope.

Submission pattern and research boundaries

A broader applicant query returned earlier Route 92 records, including K223530 for a Full Length 070 Reperfusion System and Aspiration Tubing Set, decided April 11, 2023, and K201518 for an 088 Access System, decided August 14, 2020 [5]. The sample therefore shows repeated 510(k) activity across size-labeled access and reperfusion families, but it is a small slice and does not establish the full portfolio or current commercial availability. The legal applicant name is not evidence of a parent company, brand owner or corporate structure; none is documented here. The sources cited here do not establish clinical outcomes for the 046 devices, and no performance or safety comparison between the two clearances is supported.